Interestingly, patients with rheumatoid arthritis (RA) and psoriasis were reported with a low risk of developing AD when treated with TNF blockers therapy (i.e., etanercept, adalimumab, and infliximab) (68), which suggests that blocking TNF expression may have a neuroprotective effect against AD. The gene discussed is TNF; the disease is psoriasis.